Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types.
In cli…
Analysis
Zentalis Pharmaceuticals's 360° View rank of 12 places it among the weakest overall — better than 12% of its true peers.
It's growing solidly (74) and reasonably valued (62). On safety it is highly leveraged (20), and the market shows skeptical sentiment (1). Taken together, its Combined rank of 44 reads as below its peer average.
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
68
—
—
—
Price/Earnings
14
—
—
—
Price/Book
34
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
62
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.